In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smaller But Eye-Catching Medtech Deals

Executive Summary

Not all of the key medtech deals of 2016 were blockbusters. Herein are some of the more interesting smaller deals of the year.

You may also be interested in...



Medtechs At The Wheel In New Health Care Landscape

2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.

BTG Has The Firepower For Its Next Steps In Interventional Med

UK-listed BTG PLC shares the UK life science industry's concerns about long-term negative fallout from Brexit, but it finds itself in a relatively comfortable position. The acquisitive interventional medicines company says it has plenty of firepower for more M&A.

‘A Fuse Burning At Both Ends’: German Near-Term Market Outlook For Medtech Industry

Later market launch of innovations and a hit on EBITDA are simultaneously affecting medtech companies in Germany and central Europe as they strive to keep quality uppermost while battling the most frustrating confluence of negative effects on business than most companies have ever seen.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV005008

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel